In vitro anti-Onchocerca ochengi activities of extracts and chromatographic fractions of Craterispermum laurinum and Morinda lucida

BMC Complementary and Alternative Medicine

Fidelis Cho-Ngwa²  Brice Nguesson¹  James Mbah¹  Jonathan Metuge²  Moses Samje² 

[1] Department of Chemistry, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon;Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon

关键词: Phytochemical analysis;    Toxicity;    Medicinal plants;    Onchocerciasis;   

Others  :  1086819
DOI  :  10.1186/1472-6882-14-325

 received in 2014-01-09, accepted in 2014-08-27,  发布年份 2014

【 摘 要 】

Background

Onchocerciasis caused by Onchocerca volvulus is the world’s second leading infectious cause of blindness. There is currently no cure for the disease. Ivermectin, the current drug of choice is only microfilaricidal and suboptimal response to it is increasingly being reported. Thus, in contributing to the search for a cure, crude extracts and chromatographic fractions of Craterispermum laurinum and Morinda lucida were screened in vitro, against the bovine and most popular model of the parasite, Onchocerca ochengi.

Methods

Extracted parasites were cultured in RPMI-1640 based media for 05 days in the presence of control drugs, test drugs or drug diluents only. Microfilarial motility was scored using microscopy while adult worm viability was determined biochemically by MTT/formazan colorimetry. Cytotoxicity and acute toxicity of active fractions were tested on monkey kidney epithelial cells (LLCMK2) and in Balb/c mice, respectively.

Results

Out of the 18 extracts screened, the methanolic extracts of the leaves of both plants recorded the highest activities against both the microfilariae (IC₁₀₀ of 125 μg/ml for both extracts) and adult worms (IC₁₀₀ of 250 μg/ml and 500 μg/ml for M. lucida and C. laurinum respectively). The most active chromatographic fraction was obtained from M. lucida and had an IC₅₀ of 7.8 μg/ml and 15.63 μg/ml on microfilariae and adult worms respectively, while the most active fraction from C. laurinum had an IC₅₀ of 15.63 μg/ml and 46.8 μg/ml, respectively on microfilariae and adult worms. The 50% cytotoxic concentration (CC_50s) on LLCMK2 cells ranged from 15.625 μg/ml to 125 μg/ml for the active fractions. No acute toxicity was recorded for the extracts from both plants. Phytochemical analysis of the most active fractions revealed the presence of sterols, alkaloids, triterpenes, saponins and flavonoids.

Conclusions

This study validates the use of these plants by traditional health practitioners in managing the disease, and also suggests a new source for isolation of potential lead compounds against Onchocerca volvulus.

【 授权许可】

   
2014 Samje et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 2.

【 参考文献 】

• [1]Burbelo PD, Leahy HP, Ladarola MJ, Nutman TB: A four-antigen mixture for rapid assessment of Onchocerca volvulus infection. PLoS Negl Trop Dis 2009, 3(5):e438.
• [2]Gustarven K, Hopkins A, Sauerbrey M: Onchocerciasis in the Americas: from arrival to (near) elimination. Parasit Vectors 2011, 4:205. BioMed Central Full Text
• [3]Kale OO: Onchocerciasis: the burden of the disease. Ann Trop Med Parasit 1998, 92(1):101-115.
• [4]Taylor HR, Tripis M, Cupp EN, Brotman B, Newland HS, Soboslay PT, Greene BM: Ivermectin prophylaxis against experimental Onchocerca volvulus infection in chimpanzees. Am J Trop Med Hyg 1988, 39:86-90.
• [5]Burnham G: Onchocerciasis. Lancet 1998, 351:1341-1346.
• [6]WHO (World Health Organisation): Expert committee on onchocerciasis control. Onchocerciasis and its control. Report of the WHO committee on onchocerciasis. WHO Tech Rep Ser 1995, 852:752-767.
• [7]WHO (The World Health Organization): Onchocerciasis (River blindness). WHO; 2000. Fact sheet N°. 095
• [8]Tropical Disease Research (TDR): Onchocerchiasis. 2005, 44-49. [TDR Seventeenth Programme Report: Progress 2003–2004] TDR/GEN/05.1
• [9]Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konaté L, Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JHF: Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009, 3(7):e497.
• [10]Cupp EW, Sauerbrey M, Richards F: Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Trop 2011, 120:S100-S108.
• [11]Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP: Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg 1998, 58(4):461-469.
• [12]Esum M, Wanji S, Tendongfor N, Enyong P: Co-endemicity of loiasis and onchocerciasis in the South West Province of Cameroon: implications for mass treatment with ivermectin. Trans R Soc Trop Med Hyg 2001, 95(6):673-676.
• [13]Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, Lazdins-Helds JK, Ardrey AE, Addy ET, Quartey BT, Ahmed K, Boatin BA, Soumbey-Alley EW: An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasit 2004, 98(3):231-249.
• [14]Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, Ahmed K, Boatin BA, Boakye DA, Edwards G: Thirty month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98:359-370.
• [15]Bourguinat C, Pion SDS, Kamgno J, Gardon J, Duke BOL, Boussinesq M, Prichardet RK: Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 2007, 1(1):e72.
• [16]Lustigman S, McCarter JP: Ivermectin resistance in Onchocerca volvulus: toward a genetic Basis. PLoS Negl Trop Dis 2007, 1(1):e76.
• [17]Ates DA, Erdogrul OT: Antimicrobial activities of various medicinal and commercial plant extracts. Turk J BioL 2003, 27:157-162.
• [18]WHO (The World Health Organization): Traditional Medicine. WHO; 2003. Fact sheet N°134
• [19]Nisha M, Kalyanasundaram M, Paily KP, Abidha VP, Balaraman K: In vitro screening of medicinal plant extracts for macrofilaricidal activity. Parasitol Res 2007, 100(3):575-579.
• [20]Titanji VPK, Ayafor JP, Muluh JP, Mbacham WF: In vitro killing of Onchocerca volvulus (Filaroidea) adults and microfilariae by selected Cameroonian medicinal plant extracts. Fitoterapis 1987, VIII(5):338-339.
• [21]Titanji VPK, Evehe MS, Ayafor JF, Kimbu SF: Novel Onchocerca volvulus filaricides from Carapa procera, Polyalthia suaveolens and Pachypodanthium staudtii. Acta Leiden 1990, 59:377-382.
• [22]Cho-Ngwa F, Abongwa M, Ngemenya NM, Nyongbela KD: Selective activity of extracts of Margaritaria discoidea and Homalium africanum on Onchocerca ochengi. BMC Complement Altern Med 2010, 10:62. BioMed Central Full Text
• [23]Ndjonka D, Agyare C, Lüersen K, Djafsia B, Achukwi D, Nukenine EN, Hensel A, Liebau E: In vitro activity of Cameroonian and Ghanaian medicinal plants on parasitic (Onchocerca ochengi) and free-living (Caenorhabditis elegans) nematodes. J Helminthol 2011, 85(3):304-312.
• [24]Nweze EI, Okafor JI, Njoku O: Antimicrobial activities of methanolic extracts of Trema guineensis (Schumm and Thorn) and Morinda lucida benth used in Nigerian. Biol Res 2004, 2(1):39-46.
• [25]Koroma L, Ita BN: Phytochemical compounds and antimicrobial activity of three medicinal plants (Alchornea hirtella, Morinda geminata and Craterispermum laurinum) from Sierra. Afr J Biotechnol 2009, 8(22):6397-6401.
• [26]Koumaglo K, Gbeassor M, Nikabu O, de Souza C, Werner W: Effects of three compounds extracted from Morinda lucida on Plasmodium falciparum. Planta Med 1992, 58(6):533-534.
• [27]Asuzu IU, Chineme CN: Effects of Morinda lucida leaf extract on Trypanosoma brucei brucei infection in mice. J Ethnopharmacol 1990, 30(3):307-313.
• [28]Olajide OA, Awe SO, Makinde JM, Morebise O: Evaluation of the Anti-diabetic Property of Morinda lucida Leaves in Streptozotocin-diabetic Rats. J Pharm Pharmacol 1999, 51:1321-1324.
• [29]Mccall JP, Townson H, Trees AJ: Morphometric differentiation of the Onchocerca volvulus and O. ochengi infective larvae. Trans Roy Soc Med Hyg 1992, 86:63-65.
• [30]Comley JC, Townson S, Rees MJ, Dobinson A: The application of MTT-formazan colorimetry studies on filarial worm viability. Trop Med Parasitol 1989, 40:311-316.
• [31]Townson S, Tagboto S, McGarry HF, Egerton GL, Taylor MJ: Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro. Filaria J 2006, 5:4. BioMed Central Full Text
• [32]EEC (European Economic Community): Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the member states regarding the protection of animals used for experimental and other scientific purposes. Brussels, Belgium: European Economic Community; 1986.
• [33]Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8(6):e1000412.
• [34]OECD/OCDE 420: OECD Guideline for Testing of Chemicals. 2001.
• [35]Trease GE, Evans WC: Pharmacognosy. 13th edition. Brailliar Tiridel Can: Macmillan publishers; 1989:11.
• [36]Sittie AA, Lemmich E, Olsen CE, Hviid L, Kharazmi A, Nkrumah FK, Brøgger CS: Structure-activity studies: In vitro antileishmanial and antimalarial activities of anthraquinones from Morinda lucida. Planta Med 1999, 65(3):259-261.
• [37]Fakae BB, Campbell AM, Barrett J, Scott IM, Teesdale-Spittle PH, Liebau E, Brophy PM: Inhibition of glutathione S-transferases (GSTs) from parasitic nematodes by extracts from traditional Nigerian medicinal plants. Phytother Res 2000, 14(8):630-634.
• [38]Fekam BF, Makougoum MH, Ayong LS, Wembe FE, Tume BC, Amvam ZPH, Townson S, Ngu JL: Preliminary investigation of the filaricidal activities of five essential oils on Onchocerca ochengi. Chemical Sciences 2001. Ayafor Memorial Symposium